Proteocyte Diagnostics Inc.
Proteocyte commercializes a novel molecular diagnostic test that accurately detects oral cancer before it happens to save lives and reduce health care costs.
- Stage Prototype Ready
- Industry Medical Devices and Equipment
- Location Toronto, ON, Canada
- Currency CAD
- Founded August 2011
- Employees 6
- Website proteocyte.com
Company Summary
Proteocyte commercializes Straticyte a molecular diagnostic test that accurately detects oral cancer before it happens to save lives and save health care costs.
Straticyte predicts the probability of a precancerous lesion becoming cancer in the next 5 years based on the presence of biomarkers present in the lesions.
There are 3 million precancerous lesions each year, offering an addressable market of $900 million in the more developed world.
Team
-
Ken PritzkerChief Executive Officer
Former Head, Pathology and Lab Medicine at Mount Sinai Hospital in Toronto, Dr. Pritzker is an internationally recognized leader in molecular cancer diagnostics.
-
John JordanChief Financial Officer
Financial executive with over 15 years working with entrepreneurs to create and build companies in financial and medical technology sectors.
-
Ranju RalhanChief Scientific Officer
Professor, Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Senior Scientist, Mount Sinai Hospital. Dr. Ralhan has received numerous international awards for work on cancer biomarkers.
-
Mario ThomasPresident
Formerly with Johnson & Johnson, Biochem Pharma, TerraGen Discovery, Entomed, T2C2 Bio Venture Capital and OCE. Mario has over 25 years of international experience in commercializing and financing of medical technologies.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.